Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis

Journal of the American Academy of Dermatology

Volumn 53, Issue 1 SUPPL., 2005, Pages

  Stein, Linda ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; DRUG VEHICLE;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; FOAM; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IN VITRO STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; QUALITY OF LIFE; REVIEW; SCALP; SKIN BURNING SENSATION;

EID: 20444456597     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.04.029     Document Type: Article

References (16)

1. G. Krueger, J. Koo, M. Lebwohl, A. Menter, R.S. Stern, and T. Rolstad The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey Arch Dermatol 137 2001 280 284
2. H.L. Richards, D.G. Fortune, T.M. O'Sullivan, C.J. Main, and C.E. Griffiths Patients with psoriasis and their compliance with medication J Am Acad Dermatol 41 1999 581 583
3. T.J. Franz, D.A. Parsell, R.M. Halualani, J.F. Hannigan, J.P. Kalbach, and W.S. Harkonen Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy Int J Dermatol 38 1999 628 632
4. S.R. Feldman, S.M. Ravis, A.B. Fleischer Jr., A. McMichael, E. Jones, and R. Kaplan Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis J Cutan Med Surg 5 2001 386 389
5. L. Andreassi, A. Giannetti, and M. Milani Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients Br J Dermatol 148 2003 134 138
6. L.F. Stein, A. Sherr, G. Solodkina, A.B. Gottlieb, and U. Chaudhari Betamethasone valerate foam for treatment of nonscalp psoriasis J Cutan Med Surg 5 2001 303 307
7. T.S. Housman, B.G. Mellen, S.R. Rapp, A.B. Fleischer Jr., and S.R. Feldman Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference Cutis 70 2002 327 332
8. T.J. Franz, D.A. Parsell, J.A. Myers, and J.F. Hannigan Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery Int J Dermatol 39 2000 535 538
9. M. Lebwohl, D. Sherer, K. Washenik, G.G. Krueger, A. Menter, and J. Koo A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis Int J Dermatol 41 2002 269 274
10. A.B. Gottlieb, R. Ford, and M.C. Spellman The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions J Cutan Med Surg 7 2003 185 192
11. Blum R, Stern D, Lebwohl M, Cheplo K. A randomized, investigator-blinded study of calcipotriene ointment, 0.005% and clobetasol propionate foam, 0.05% in the sequential treatment of localized plaque-type psoriasis. Poster presented at the 62nd Annual Meeting of the American Academy of Dermatology, Washington, DC, Feb 6-11, 2004.
12. J. Hughes, and M. Rustin Corticosteroids Clin Dermatol 15 1997 715 721
13. M. Milani, S. Antonio Di Molfetta, R. Gramazio, C. Fiorella, C. Frisario, and E. Fuzio Efficacy of betamethasone valerate 0.1% thermophobic foam in seborrhoeic dermatitis of the scalp: an open-label, multicentre, prospective trial on 180 patients Curr Med Res Opin 19 2003 342 345
14. G. Mancuso, A. Balducci, C. Casadio, P. Farina, M. Staffa, and L. Valenti Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: a multicenter, prospective, randomized, controlled, investigator-blinded trial Int J Dermatol 42 2003 572 575
15. Jackson JM, Fowler J, Cheplow K. The use and effectiveness of clobetasol propionate foam, 0.05% in the treatment of hand dermatitis and its effectiveness on quality of life. A double-blind vehicle-controlled trial. Poster presented at the 62nd Annual Meeting of the American Academy of Dermatology Washington, DC, Feb 6-11, 2004.
16. K.G. Bergstrom, K. Arambula, and A.B. Kimball Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis Cutis 72 2003 407 411